FTC Challenges Amgen's Patent Play in Enbrel Antitrust Case
AMGN sits 63% above its 52-week low of $269.77 on light trading volume (0.3× avg).
Summary
The FTC filed an amicus brief arguing Amgen's acquisition of patent applications for Enbrel is subject to antitrust scrutiny, directly challenging the company's appeal that such applications are immune from liability. This escalates legal risk around Enbrel, a blockbuster arthritis drug, and could threaten Amgen's ability to block low-cost competitors. The brief follows a federal judge's earlier denial of Amgen's motion to dismiss the private antitrust suit. The FTC's stance signals heightened regulatory focus on pharmaceutical patent strategies, potentially impacting Amgen's market exclusivity for Enbrel.
At the time of this announcement, AMGN was trading at $438.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $237.2B. The 52-week trading range was $269.77 to $443.20. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.